碳铂(cis-diammine-1,1-cyclobutane dicarboxylate platinum,简称CBDCA,JM公司定名JM_8)是第二代铂类抗癌新药。Cleare等首先发现它的抗癌活性,并证实其毒副作用低于顺氯氨铂(CDDP)。随后陆续发表了有关CBDCA的动物和人体肿瘤疗效、毒性、药代动力学方面的研究报道。除进一步证实它抗瘤谱较宽、毒性低之外,还发现它的药理性质与CDDP明显不同。 Carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum, abbreviated as CBDCA, JM company named JM_8) is the second generation of platinum anticancer drugs. Cleare et al. first discovered its anticancer activity and confirmed that its side effects were lower than that of cisplatin (CDDP). Subsequently, reports on the efficacy, toxicity, and pharmacokinetics of CBDCA in animal and human tumors were published. In addition to further confirmation of its broad spectrum of anti-tumor and low toxicity, its pharmacological properties were also found to be significantly different from CDDP.